Study suggests benefits of raloxifene in women with schizophrenia symptoms

Abstract

A 120‐mg daily dose of the selective estrogen receptor modulator raloxifene significantly reduced illness severity when used with an antipsychotic in adult women with persistent symptoms of schizophrenia, a new study has found. The study's lead author pointed out that the results demonstrate the potential importance of hormonal factors in women who have not responded adequately to conventional treatment for psychotic illness. Study results were published online July 20 in JAMA Psychiatry.